Therefore, any resistance mechanism that develops in the various components of the immune microenvironment in the context of BRAF/MAPK arising from the immune components within the tumor microenvironment can compromise the therapeutic benefit, necessitating further investigation [124,140]. This evidence concerns the gene BRAF and neoplasm.